Metrics
5 Record Views
- Title
- P636: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES
- Creators
- Michal Kwiatek - Centrum Medyczne Pratia, Poznan, PolandGuru Subramanian Guru Murthy - Medical College of WisconsinMarc Hoffmann - The University of Kansas Cancer CenterLindsey Roeker - Memorial Sloan Kettering Cancer CenterBenoit Tessoulin - Centre Hospitalier Universitaire de NantesAlexey Danilov - City Of Hope National Medical CenterAlvaro J. Alencar - University of MiamiNirav N. Shah - Medical College of WisconsinHerve Ghesquieres - Hôpital Lyon SudSteven Le Gouill - Institute CurieWojciech Jurczak - Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, PolandAnthony R. Mato - Memorial Sloan Kettering Cancer CenterVishalkumar Patel - Loxo@Lilly, Stamford, CT, United StatesYingying Guo-Avrutin - Loxo@Lilly, Stamford, CT, United StatesJames M. Pauff - Loxo@Lilly, Stamford, CT, United StatesMaciej Kazmierczak - Centrum Medyczne Pratia, Poznan, Poland
- Publication Details
- HemaSphere, Vol.7, p.e216785f
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031923255202976